OKYO Pharma

Youtube Subscribe

Open: 1.83 Close: 1.74 Change: -0.09

Don't invest before reading what an AI found about OKYO Pharma.

How much time have you spent trying to decide whether investing in OKYO Pharma? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about OKYO Pharma are: …

Concept Map

Semantic Network

Stock Summary

OKYO Pharma Limited engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain. Its lead preclinical product candidate is OK-101 for the treatment of dry eye disease. OK-201 is a bov.

Today's Summary

OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. OKYo Pharma Limited (NASDAQ: OKYYO) is a clinical stage biopharaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease. OKYO Pharma Ltd (NASDAQ:OKYO) is down 10.2% at $2.03 at last check, after the pharmacy company announced the filing of a new investigational drug application for OK-101. The $21 level has rejected the stock on several occasions this year, though it is still up.

Today's News

OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. OKYo Pharma Limited (NASDAQ: OKYYO) is a clinical stage biopharaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease. OKYO Pharma Ltd (NASDAQ:OKYO) is down 10.2% at $2.03 at last check, after the pharmacy company announced the filing of a new investigational drug application for OK-101. The $21 level has rejected the stock on several occasions this year, though it is still up.

Stock Profile

"OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom."

Keywords

The game is changing. There is a new strategy to evaluate OKYO Pharma fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about OKYO Pharma are: Pharma, company, OKYO, Ltd, inflammatory, eye, operate, and the most common words in the summary are: state, united, read, allen, williams, therapeutic, pharma, . One of the sentences in the summary was: OKYo Pharma Limited (NASDAQ: OKYYO) is a clinical stage biopharaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #state #united #read #allen #williams #therapeutic #pharma.

Read more →

Youtube Subscribe

---